Survey of bone marrow megakaryocytes stained with anti-Aurora-B/AIM-1 antibody
. | Percentage of AIM-1-positive cells (n)* . | . | |
|---|---|---|---|
. | CD41 + cells < 10 μm in diameter . | CD41 + cells > 10 μm in diameter . | |
| WT | 0 (65) | 1 (1263) | |
| TG58 | 85.3 ± 14.4 (64) | 1 (1531)† | |
| TG74 | 82.4 ± 16.9 (98) | 1 (1434) | |
. | Percentage of AIM-1-positive cells (n)* . | . | |
|---|---|---|---|
. | CD41 + cells < 10 μm in diameter . | CD41 + cells > 10 μm in diameter . | |
| WT | 0 (65) | 1 (1263) | |
| TG58 | 85.3 ± 14.4 (64) | 1 (1531)† | |
| TG74 | 82.4 ± 16.9 (98) | 1 (1434) | |
Numbers in parentheses (n) reflect CD41+ cells (megakaryocytes) surveyed in each category. These numbers are smaller for cells whose diameters measure less than 10 μm because they are scarce (ie, they comprise up to 10% of the total number of megakaryocytes). Given that only 10% to 15% of the megakaryocytes in the marrow are cell cycling and that the length of the M- phase is only one tenth that of the whole cell cycle,37 it was not surprising to note that approximately 1% of the large megakaryocytes displayed intense staining of Aurora-B/AIM-1 localized to the nucleus. This pattern was similar in wild-type or transgenic mice.
Only strongly staining cells were scored.
Approximately 20% of the megakaryocytes examined displayed weak, diffused staining of Aurora-B/AIM-1 (over background) throughout the cell.